glp 1 agonist osteoporosis GLP-1s and Bone Health: What the Evidence Says About Semaglutide, Bone Density, and Muscle Loss AAOS: GLP-1 receptor agonist use

Side Effects: As a GLP-1 therapy, common side effects are typically gastrointestinal, including nausea, vomiting, and diarrhea.

Individual results vary

The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022

| 228 comments on LinkedIn

But despite widespread use of these drugs by perimenopausal women, research has largely ignored the unique risks and potential opportunities for optimizing health that GLP-1s may pose for this population.

This article explores current clinical evidence, provider decision-making frameworks, and how genetic insights may inform a personalized conversation with your healthcare